Evidence map›Paper›PMID 38467687›Full record

ArticleScientific reports2024

A drug stabilizable GAL80

Vaishnavi Kogenaru, Mark Isalan, Manjunatha Kogenaru

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vaishnavi KogenaruRicards Lodge High School, Lake Road, Wimbledon, London, SW19 7HB, UK.
Mark IsalanDepartment of Life Sciences, Imperial College London, London, SW7 2AZ, UK.
Manjunatha KogenaruDepartment of Life Sciences, Imperial College London, London, SW7 2AZ, UK. Manjunatha.Kogenaru@nyulangone.org.
Imperial College London · GB

Funding

Wellcome Trust 102944/Z/13/Z
6 · The paper itself

Abstract

The binary GAL4-UAS expression system has been widely used in Drosophila to achieve tissue-specific expression of genes. To further allow for simultaneous spatial and conditional control of gene expression in existing GAL4 expression lines backgrounds, temperature and chemical controllable GAL80 variants have been engineered. Here we add a new drug stabilizable GAL80

Indexed as

DrosophilaDrosophila ProteinsAnimalsCRISPR-Cas SystemsGene ExpressionRNA, Guide, CRISPR-Cas SystemsTranscription FactorsDrosophila ProteinsGAL4 protein, DrosophilaRNA, Guide, CRISPR-Cas SystemsTranscription FactorsGene functionGene toxicityLethality geneProtein designTransgene expression

Identifiers

PMID38467687
PMCPMC10928143
OpenAlexW4392658406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.